Soleus Capital Management, L.P. 89bio, Inc. Transaction History

Soleus Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $1.8 Million - $2.32 Million	119,533 Added 52.77%	346,033 $5.34 Million
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $3.79 Million - $5.89 Million	-267,500 Reduced 54.15%	226,500 $4.29 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $1.21 Million - $1.95 Million	115,000 Added 30.34%	494,000 $7.52 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $270,480 - $623,770	49,000 Added 14.85%	379,000 $4.82 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $996,600 - $2.31 Million	330,000 New	330,000 $1.91 Million

167

109M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $532M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.